To attract more new drugs still at the early stages of development at bioventures to Japan, the country has kick-started an official plan to open the first full-time foreign office of its Pharmaceuticals and Medical Devices Agency (PMDA), in Washington D.C.
Breaking Barriers: Japan's PMDA To Open First Global Office, In D.C.
Plus Bangkok Training Hub
Through a new full-time office in the US capital, Japan's drug regulator aims to provide essential regulatory information to help US bioventures enter the Japanese market at an early stage.
More from Japan
More from Asia
• By
A new annual report from China's CDE shows a rise in overall product approvals but a fall in the transition rate for conditional to full approvals, possibly signalling more stringent requirements.
• By
Japan adds four new pediatric vaccines, including for MMRV and norovirus, to a list of priority vaccines eligible for assistance in regulatory processing.
• By
While CMC glitches linger over a US NDA for Elevar/Hengrui’s novel liver cancer combination following a second complete response letter, the separate issue of underrepresentation of US patients in multiregional trials is looming large after new FDA draft guidance last year.